Press Releases - IDRx
Nov 2, 2023 · IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)
News | IDRx
Intelligently designed precision therapies to transform cancer care
Is GSK prepping a $1bn takeover bid for IDRx? | pharmaphorum
1 day ago · GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST).
IDRx Announces Updated Phase 1 Data from Ongoing Phase 1/1b …
IDRx has aligned with the FDA on fundamental elements of the trial design, dose, and statistical analysis for StrateGIST 3, a global, randomized, Phase 3 registrational trial which will evaluate IDRX-42 as a second-line therapy in patients diagnosed with metastatic and/or unresectable GIST with disease progression on, or intolerance to ...
GSK is said to be nearing $1B deal to acquire U.S. biotech IDRx
British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times reported ...
GSK Nears $1 Billion Deal for Biotech Company IDRx
2 days ago · GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio.
GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 ...
1 day ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial ...
IDRx Reports Updated Preliminary Phase 1 Data from Ongoing …
PLYMOUTH, Mass., June 03, 2024 -- (BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today...
GSK in advanced talks to purchase U.S. biotech IDRx, FT reports
2 days ago · GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal tumors, the Financial Times’ Oliver Barnes and ...
IDRx Announces $120 Million Series B Financing to Advance …
PLYMOUTH, Mass., August 07, 2024 -- (BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies,...
- Some results have been removed